Abstracts Archive - Page 662 of 2425 - ACR Meeting Abstracts

Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 0517 • ACR Convergence 2020
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study
Thomas Garvey¹, Cynthia Crowson², Matthew J. Koster³ and Kenneth Warrington³, ¹Mayo Clinic Rochester, Apple Valley, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection. The…
Abstract Number: 0516 • ACR Convergence 2020
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Sebastian Unizony¹, Shalini V. Mohan², Jian Han² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
Abstract Number: 0522 • ACR Convergence 2020
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Karen Costenbader⁴, Raymond Naden⁵ and Doruk Erkan⁶, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, ³Hospital for Special Surgery, New York, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria for Antiphospholipid Syndrome (APS). The methodological approach includes four…
Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Flavio Signorelli¹, Gustavo Balbi², Eloisa Bonfa³, Eduardo Borba⁴ and Danieli Andrade⁵, ¹Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, ²Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0529 • ACR Convergence 2020
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
Savino Sciascia¹, Massimo Radin¹, Irene Cecchi¹, Daniela Rossi¹ and Dario Roccatello², ¹University of Torino, Torino, Italy, ²S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
Abstract Number: 0524 • ACR Convergence 2020
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
Yann Nguyen¹, Cécile Yelnik², Nathalie Morel³, Romain Paule⁴, Pierre-Yves Hatron², Romain Stammler⁵, Léo Plaçais³, Jean-Charles Piette⁶, Luc Mouthon⁷, Eric Hachulla⁸, Marc Lambert², Le Guern Véronique³ and Nathalie Costedoat-Chalumeau⁹, ¹1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ²Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, ³National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, ⁴Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, ⁵National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, ⁶Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ⁹APHP, Université de Paris, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
Abstract Number: 0519 • ACR Convergence 2020
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
Rohan Willis¹, E Nigel Harris², Vijaya Murthy³, Zurina Romay-Penabad¹, Alvaro Schleh⁴, Monica Smikle², Karel De Ceulaer², Anne Tebo⁵, Troy Jaskowski⁶, Marta Guerra⁷, David Ware Branch⁸, Jane Salmon⁷, Michelle Petri⁹ and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³University of Texas Medical Branch, League City, TX, ⁴Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁵Department of Pathology, University of Utah, Salt Lake City, ⁶ARUP Laboratories, Salt Lake City, UT, ⁷Hospital for Special Surgery, New York, NY, ⁸University of Utah, Salt Lake City, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
Abstract Number: 0532 • ACR Convergence 2020
State-Specific Percentage of Adults with Arthritis Who Report Both Severe Joint Pain and Physical Inactivity and Their Characteristics, United States, Behavioral Risk Factor Surveillance System, 2017
Dana Guglielmo¹, Louise Murphy¹, Jennifer Hootman¹, Michael Boring¹, Kristina Theis¹, Charles Helmick¹, Susan Carlson¹, Yong Liu¹, Hua Lu¹ and Janet Croft¹, ¹Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: About one in four (27%) US adults with arthritis have severe joint pain, and only 36% meet the Physical Activity Guidelines for Americans. While…
Abstract Number: 0535 • ACR Convergence 2020
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
Jasvinder Singh¹, John Richards², Elizabeth Chang³, Toupin-April, Karine Toupin-April⁴ and Jennifer Barton⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ³Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, ⁴VA Portland Oregon, Portland, OR, ⁵Oregon University, Portland, OR
Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…
Abstract Number: 0536 • ACR Convergence 2020
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
Bjoern Buehring¹, Anna Berrisch², Ioana Andreica³, Styliani Tsiami⁴, David Kiefer³, Uta Kiltz², Xenofon Baraliakos² and Juergen Braun², ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…
Abstract Number: 0531 • ACR Convergence 2020
The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records
Sunali Goonesekera¹, Ankit Bansal¹, Swarali Tadwalkar² and Alison Isherwood³, ¹Decision Resources Group, Part of Clarivate, Boston, MA, ²Decision Resources Group, part of Clarivate, Bangolore, India, ³Decision Resources Group, part of Clarivate, London, United Kingdom
Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
Abstract Number: 0539 • ACR Convergence 2020
Sports with a Bat or Racket Are Not Associated with Thumb-base Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Grace Lo², Mary Roberts³, Matthew Harkey⁴, Lena Schaefer⁵, Ida Kristin Haugen⁶, Stacy Smith⁷, Jeffrey Duryea⁷, Bing Lu⁸, Charles Eaton⁹, Marc Hochberg¹⁰, Rebecca Jackson¹¹, C. Kent Kwoh¹², Michael Nevitt¹³ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Michael E. Debakey VA Medical Center, Baylor College of Medicine, Houston, TX, ³Center for Primary Care & Prevention, Alpert Medical School of Brown University, Pawtucket, RI, ⁴University of Massachusetts, Worcester, MA, ⁵Radiology Department, Klinikum Nürnberg Süd, Nürnberg, Germany, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁹Brown University, Pawtucket, RI, ¹⁰University of Maryland School of Medicine, Baltimore, MD, ¹¹Ohio State University, Columbus, OH, ¹²University of Arizona of Arizona Arthritis Center and Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, ¹³Department of Epidemiology and Biostatistics, University of California San Francisco, Orinda, CA
Background/Purpose: Sports that require the use of a racket or bat to propel a ball (e.g., baseball, softball, tennis) expose the thumb-base to repetitive high-velocity…
Abstract Number: 0534 • ACR Convergence 2020
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
Meghna Jani¹, Belay Yimer¹, Therese Sheppard¹, Mark Lunt¹ and William Dixon¹, ¹Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom
Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].